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Expression of a Knocked-In AML1-ETO Leukemia Gene Inhibits
the Establishment of Normal Definitive Hematopoiesis and Directly
Generates Dysplastic Hematopoietic Progenitors
By Tsukasa Okuda, Zhongling Cai, Shouli Yang, Noel Lenny, Chuhl-joo Lyu, Jan M.A. van Deursen,
Hironori Harada, and James R. Downing
The t(8;21)-encoded AML1-ETO chimeric product is believed
to be causally involved in up to 15% of acute myelogenous
leukemias through an as yet unknown mechanism. To di-
rectly investigate the role of AML1-ETO in leukemogenesis,
we used gene targeting to create an AML1-ETO ‘‘knock-in’’
allele that mimics the t(8;21). Unexpectedly, embryos hetero-
zygous for AML1-ETO (AML1-ETO/1) died around E13.5
from a complete absence of normal fetal liver–derived defini-
tive hematopoiesis and lethal hemorrhages. This phenotype
was similar to that seen following homozygous disruption of
either AML1 or CBFb. However, in contrast to AML1- or
CBFb-deficient embryos, fetal livers from AML1-ETO/1 em-
bryos contained dysplastic multilineage hematopoietic pro-
genitors that had an abnormally high self-renewal capacity
in vitro. To further document the role of AML1-ETO in these
growth abnormalities, we used retroviral transduction to
express AML1-ETO in murine adult bone marrow–derived
hematopoietic progenitors. AML1-ETO–expressing cells were
again found to have an increased self-renewal capacity and
could be readily established into immortalized cell lines in
vitro. Taken together, these studies suggest that AML1-ETO
not only neutralizes the normal biologic activity of AML1 but
also directly induces aberrant hematopoietic cell prolifera-
tion.
r 1998 by The American Society of Hematology.
THE (8;21)(q22;q22) TRANSLOCATION is one of themost frequent karyotypic abnormalities detected in acute
myelogenous leukemia (AML), accounting for approximately
40% of de novo AML cases that have M2 morphology in the
French-American-British (FAB) classification.1 As a result of
this translocation, the gene encoding the AML1 (CBFA2)
transcription factor from chromosome 21 is fused to the eight
twenty-one gene (ETO, also known as MTG8 and CBFA2T1) on
chromosome 8.2-5 This fusion gene encodes a chimeric AML1-
ETO protein consisting of the N-terminus of AML1 fused in
frame to the C-terminus of ETO. The fact that the t(8;21) is the
sole cytogenetic abnormality in the majority of these cases
suggests that AML1-ETO plays a critical role in the establish-
ment of the leukemia clone.
One of the targets of this translocation, AML1, is the
DNA-binding subunit of the AML1/CBFb transcription factor
complex and binds the enhancer core motif, TGT/cGGT.6,7
AML1’s DNA-binding affinity is increased through heterodimer-
ization with CBFb, and both its DNA-binding and interaction
with CBFb are mediated through a central domain with high
homology to the Drosophila segmentation gene, runt.6,8,9 The
AML1-ETO chimeric product retains this domain and therefore
also binds the core enhancer sequence and interacts with
CBFb.6,10 Compared with AML1, relatively little is known
about ETO, the other target of this translocation. Although ETO
contains a zinc finger motif and appears to be the mammalian
homologue of the Drosophila gene nervy,11 no direct DNA-
binding activity has been detected, nor has its function been
identified.12
Transcriptional regulation by AML1 through the enhancer
core motif has been shown to be important for the tissue specific
expression of a number of hematopoietic specific genes includ-
ing interleukin-3 (IL-3),13 granulocyte-macrophage colony-
stimulating factor (GM-CSF),14 the receptor for CSF-1 (CSF-
1R),15 myeloperoxidase,16 and subunits of the T-cell antigen
receptor (TCR).8,17 By creating mice deficient in AML1/CBFb,
we18 as well as others19-21 have shown that the AML1/CBFb
transcription factor complex is essential for the establishment of
definitive hematopoiesis.
Consistent with a critical role in hematopoiesis, the genes
encoding the AML1/CBFb transcription factor complex are the
most frequent targets of chromosomal abnormalities in human
leukemia. In addition to t(8;21), AML1 fusion products are
generated as a result of the t(3;21) (AML1-EVI1) in myelodys-
plasia and blast crisis of chronic myelogenous leukemia,22-24
and the t(12;21) (TEL-AML1), the most frequent translocation
in pediatric acute lymphoblastic leukemia.25-28 Similarly, the
CBFb gene is fused to the smooth muscle myosin heavy chain
gene, MYH11, as a result of the inv(16) or t(16;16) in the
majority of AML cases with M4Eo FAB morphology.29-30
Biochemical studies of these translocation-encoded fusion
products suggest that both AML1 and CBFb chimeric products
function, at least in part, to dominantly interfere with normal
AML1/CBFb-mediated transcription.10,31-34 For example,
AML1-ETO represses transcription of reporter genes driven by
the TCRb enhancer10 or the GM-CSF promoter,31 and this
activity is dependent on a putative repression domain within the
C-terminus of ETO.32
To directly investigate the in vivo mechanism through which
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AML1-ETO contributes to leukemogenesis, we designed a
‘‘knock-in’’ strategy to generate mice containing a single allele
of AML1-ETO (AML1-ETO/1) whose expression is regulated
by the endogenous transcriptional regulatory elements of mu-
rine AML1. Our analysis shows that AML1-ETO both neutral-
izes normal AML1/CBFb activity and directly generates signals
that lead to the generation of abnormal hematopoietic progeni-
tors.
MATERIALS AND METHODS
Construction of AML1-ETO knock-in targeting vector. A silent
A = G mutation at codon 122 was introduced by site-directed
mutagenesis into the human AML1-ETO cDNA (a gift from Dr S.
Hiebert, Vanderbilt University, Nashville, TN) to create a SacII
cleavage site that is in an identical position to a SacII site within exon 4
of murine AML1. A 1.9-kb SacII fragment from this cDNA, which
included 62 bp of AML1 exon 4, all of exon 5, and the entire fused
portion of ETO, was then inserted into the murine AML1 exon 4 SacII
site within a 12-kb murine genomic AML1 clone.18 This resulted in an in
frame fusion of the first 95 bp of murine AML1 exon 4 to the remaining
portion of the human AML1-ETO cDNA. A 470-bp fragment containing
the polyadenylation signal from the rabbit globin gene excised from
pEµSR,35 followed by a 1.7-kb HSV-tk promoter-neomycin resistance
cassette,18 inserted in the opposite transcriptional orientation was
inserted immediately 38 of the 1.9-kb cDNA fragment. Finally, a 1.2-kb
HSV-tk promoter-diphtheria toxin-A negative selection cassette was
inserted at the 38 end of the construct. The vector was linearized at a
unique Not I site located at the 38 end of the construct and introduced
into embryonic stem (ES) cells.
Production of chimeric mice. The linearized targeting vector (50
µg) was electroporated into E14 ES cells as previously described.18
G418-resistant clones were analyzed for homologous recombination by
Southern analysis of Xba I–digested DNA hybridized with 58 (0.4 kb) or
38 (0.5 kb) AML1 fragments derived from murine genomic sequences
outside the vector. Clones with homologous recombination of the
targeting vector were then assessed by reverse transcriptase-polymerase
chain reaction (RT-PCR) for expression of the fusion gene. Oligonucleo-
tide primers from murine AML1 exon 3 (58-CCAGCAAGCTGAG-
GAGCGGCG-38) and human ETO (58-AGGCTGTAGGAGAATGG-
38) were used for PCR amplification, and the products were analyzed by
Southern analysis using a murine AML1 exon 4 specific oligonucleotide
probe (58-GTGGTGGCACTGGGGGACGT-38) for detection. AML1-
ETO/1 clones with undifferentiated morphology and normal karyo-
types were injected into C57BL/6 blastocysts. Male chimeras were bred
with C57BL/6 females and tail biopsy specimens of agouti offspring
were screened for the presence of the knock-in allele by Southern
analysis.
Histology. Embryos were removed from the uterus, dissected free
from the fetal membranes, and inspected under a dissecting microscope
for evidence of gross abnormalities. Fetal tissues were then obtained for
genotyping and cells from yolk sacs or fetal livers were isolated under
sterile conditions and used for in vitro hematopoietic colony assays.
Embryos were fixed in Bouin’s solution, embedded in paraffin, and
sections stained with hematoxylin and eosin. Peripheral blood was
collected in 10 mmol/L EDTA and smears stained with Wright-Giemsa.
In vitro culture of hematopoietic cells. Cells from yolk sacs, fetal
livers, or bone marrows were obtained and cultured in methylcellulose
semisolid media containing a combination of colony stimulating factors
as previously described.18 Cell aggregates containing more than 50 cells
were counted as colonies. Cytocentrifuge preparations of hematopoietic
colonies were stained with Wright-Giemsa for morphologic examina-
tion or for the presence of nonspecific esterase (alpha naphthyl butyrate)
cytochemical activity. In replating experiments, either individual hema-
topoietic colonies or all of the cells from the primary culture were
collected, washed, and then replated at 1 to 3 3 104 cells/plate into new
methylcellulose cultures under conditions identical to those used for the
primary cultures. Colonies were scored as above and subsequent
replatings were performed in an identical fashion. Cell lines were
generated by harvesting colonies from a single plate and growing the
cells in liquid cultures containing RPMI 1640 media containing 10%
fetal calf serum, 2 mmol/L L-glutamine, 50 U/mL penicillin G, 50
µg/mL streptomycin, and 10 ng/mL of IL-6 and SCF and 2 ng/mL of
IL-3.
Western blot and immunophenotypic analysis. Cells were lysed in
boiling RIPA lysis buffer, electrophoretically separated on a 10%
denaturing polyacrylamide gel, and transferred to a nitrocellulose
membrane. Proteins were detected using affinity purified AML-1
N-terminal peptide antiserum6 or affinity purified ETO N-terminal
peptide antiserum10 and visualized with supersignal ULTRA chemilumi-
nescence substrate (Pierce, Rockford, IL). Cell surface antigens were
detected by a standard direct immunofluorescence assay using phycoery-
thrin-conjugated monoclonal antibodies (MoAb) from PharMigen (San
Diego, CA) to Ly-6G (Gr-1), CD116 (MAC-1), c-kit, Sca-1, and Thy-1.
Fluorescence activity was analyzed on an FACScan (Becton Dickson,
San Jose, CA). Isotypically matched MoAbs at the same protein
concentration were used as negative controls in all experiments.
Production of retroviral stocks and infection of murine bone marrow
cells. A human AML1-ETO cDNA10 was inserted into the retroviral
vector MSCVneo36 to generate MSCV/AML1-ETOneo. Helper-free
retrovirus was generated by transfecting the Bosc23 packaging cell
line37 with MSCVneo or MSCV/AML1-ETOneo DNA, and retroviral
containing supernatants were collected and stored at 280°C. Superna-
tants were titered on NIH3T3 cells in G418 containing media as
described previously.38
Murine bone marrow cells were obtained from the femur and tibia of
8- to 10-week-old female BALB/cByJ mice 2 days following an
intraperitoneal injection of 150 mg/kg of 5-FU (SoloPak Laboratories,
Elk Grove Village, IL). Harvested cells were prestimulated for 48 hours
with IL-6 and SCF as previously described38 and then infected on
fibronectin fragment CH-296-(Takara Shuzo, Otsu, Japan) coated
bacterial dishes with 10 mL of viral supernatant supplemented with 100
ng/mL SCF and 100 ng/mL IL-6. Fresh viral supernatant was added
after 2 hours and again after 22 hours, and the infection continued for a
total of 48 hours. Infected cells were then plated directly in methycellu-
lose medium containing G418 at a concentration of 1.0 mg/mL, and the
hematopoietic growth factors IL-3, IL-6, and SCF. Serial replating of
hematopoietic colonies was performed as described above. Cell lines
were established by growing cells in liquid cultures containing Iscove’s
media containing 15% fetal calf serum (FCS), 2 mmol/L glutamine, 10
ng/mL of IL-3 and IL-6, 50 ng/mL SCF, 0.1 mmol/L 2-mercaptoentha-
nol, 10 µg/mL insulin, 200 µg/mL transferrin, and 3 U/mL erythropoietin.
RESULTS
Embryonic lethality, absence of definitive fetal liver hemato-
poiesis, and lethal hemorrhages in mice heterozygous for the
AML1-ETO knock-in allele. To create an AML1-ETO chi-
meric gene that mimics that formed by the t(8;21), we fused
human AML1-ETO sequences in frame to murine AML1 exon 4
(Fig 1). This targeting strategy resulted in the generation of a
murine/human hybrid AML1-ETO gene whose expression is
controlled by endogenous murine AML1 regulatory sequences.
Three independent AML1-ETO/1 ES cell clones with normal
ploidy were analyzed and shown by RT-PCR to express
AML1-ETO (Fig 1). In undifferentiated ES cells, endogenous
murine AML1 is expressed and can be detected by RT-PCR
(data not shown).
Chimeric male mice generated from two independent AML1-
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ETO/1 ES cells were bred with wild-type C57BL/6 females,
and agouti pups were obtained, showing germline transmission
of the ES cell–derived genome. Of the 94 live agouti pups
genotyped, none contained the AML1-ETO knock-in allele,
suggesting that expression of AML1-ETO was embryonic lethal
(Table 1). To define the stage of embryonic development at
which expression of AML1-ETO is lethal, we analyzed em-
bryos between 10.5 and 14.5 days of gestation. At E10.5 and
E11.5 the majority of AML1-ETO/1 embryos were viable and
showed no significant morphologic abnormalities when com-
pared with their normal litter mates (Table 1 and data not
shown). However, by E12.5 a significant proportion of the
AML1-ETO/1 embryos were dead, and by E14.5 no viable
embryos with the knock-in allele were detected (Table 1). From
E12.5 to E13.5 the AML1-ETO/1 embryos showed normal
overall organ development and were equal in size to their
control litter mates; however, the AML1-ETO/1 embryos were
identifiable by marked fetal liver pallor and by massive
hemorrhages within the ventricles of the central nervous system
(CNS) and within the pericardial cavity and the soft tissues of
the back (Fig 2).
On microscopic examination, the CNS hemorrhages ap-
peared to originate within midbrain parenchyma, the dorsal root
ganglia, and the ganglia of the VII/VIII cranial nerve complex
(Fig 2). Focal hemorrhages were detected within these structures
as early as E11.5. Apoptotic neural cells were also identified
within these ganglia; however, no differences in the num-
ber of apoptotic cells were noted between normal and AML1-
ETO/1 embryos. In addition, we saw no evidence of necrosis in
the developing neural structures before the onset of bleeds.
Fig 1. Generation of an AML1-ETO chimeric gene
by homologous recombination. (A) Schematic of
AML1 cDNA, partial murine AML1 genomic locus,
and replacement vector containing a partial human
AML1-ETO cDNA, polyadenylation signal (pA), and
the positive selection neomycin resistance cassette
(Neor) and negative selection diphtheria toxin-A
cassette (DT-A). Arrows indicate the position of the
AML1-ETO fusion and the transcriptional orienta-
tion of selection cassettes. The structure of the
targeted allele and the chimeric AML1-ETO cDNA is
shown, as are the primers used for RT-PCR amplifi-
cation and detection of the AML1-ETO fusion tran-
script. Use of AML1 genomic probes A or B on Xba
I–digested DNA allows resolution of wild-type and
targeted alleles. (B) Southern analysis of control
(CTR) and AML1-ETO knock-in (KI) ES cell clones.
(C) RT-PCR analysis of CTR and KI ES cell clones.
AML1-ETO mRNA was amplified using primers 1
and 2, and products were hybridized with the
murine AML1-specific oligonucleotide 3. Amplifica-
tion was also performed for HPRT mRNA as a
control for the presence of amplifiable RNA.
Table 1. Genotype and Phenotype of Embryos Derived From
AML1-ETO Chimeric Males Mated with Normal Females
Stages
Number
of Pups
Genotype Phenotype
1/1 1/KI* Hemorrhage Dead
E10.5 48 34 14 0 0
E11.5 58 38 20 1 1
E12.5 62 37 25 21 5
E13.5 60 39 21 21 10
E14.5 32 18 14 14 14
At birth 94 94 0 — —
*KI, AML1-ETO knock-in allele.
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The major developmental defect identified in the AML1-
ETO/1 embryos was the complete absence of definitive fetal
liver–derived hematopoiesis. Primitive yolk sac–derived hema-
topoiesis was intact, as assessed by the absence of overt anemia
and by normal morphology of primitive nucleated erythrocytes.
By contrast, microscopic sections of the fetal liver revealed the
complete absence of definitive fetal liver–derived hematopoi-
esis (Fig 2). Within the liver no erythroid, myeloid, or mega-
karyocytic progenitors were identified, and only scattered
primitive nucleated erythrocytes were seen. Peripheral blood
smears from E11.5-E13.5 AML1-ETO/1 embryos contained
only primitive nucleated erythrocytes and lacked visible plate-
lets (Fig 2). By contrast, platelets and definitive erythrocytes
were easily identified within smears from control litter mates. In
Fig 2. Phenotype of E12.5
AML1-ETO/1 and wild-type (WT)
embryos. (Top panels) AML1-
ETO/1 embryos were identical
in size to wild-type littermates,
but were easily identifiable by
the presence of fetal liver pallor
and massive hemorrhages within
the ventricles of the CNS and the
soft tissues of the back. (Second
panels) Sections showing hemor-
rhages within the dorsal root
ganglia of AML1-ETO/1 em-
bryos. (Third panels) Sections of
the fetal liver from AML1-ETO/1
embryos showing a complete ab-
sence of hematopoietic precur-
sors with only rare primitive
nucleated erythrocytes seen
within hepatic sinusoids. By con-
trast, sections of the fetal liver
from control littermates show
numerous erythroblasts and
scattered myeloblasts and mega-
karyocytes. (Bottom panels)
Smears of peripheral blood show
the absence of definitive erythro-
cytes and platelets in the AML1-
ETO/1 embryos. By contrast, nu-
merous enucleated definitive
erythrocytes and platelets are
seen in the peripheral blood from
wild-type embryos.
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addition, neutrophils and monocytes were seen upon scanning
the smears from normal E11.5-E13.5 embryos but were absent
from AML1-ETO/1 smears (data not shown).
Expression of AML1-ETO leads to the generation of dysplas-
tic hematopoietic progenitors. To further characterize the
hematopoietic defect identified in AML1-ETO/1 embryos, we
analyzed cells from yolk sacs and fetal livers for in vitro
hematopoietic colony forming activity. Cells from the yolk sacs
of viable E10.5 embryos were plated in methycellulose media
under conditions optimal for the development of myeloid,
erythroid, and mixed colonies. At this stage of development no
primitive hematopoietic progenitors are detected under the in
vitro culture conditions used,39 and thus all hematopoietic
colonies detected in these assays are of definitive origin.
Numerous colonies grew in cultures of yolk sacs from E10.5
wild-type embryos, whereas only rare granulocytic or granulo-
cytic-monocytic colonies were identified in yolk sac cultures
from E10.5 AML1-ETO/1 embryos (Table 2). Similarly, numer-
ous definitive hematopoietic colonies were detected in cultures
of fetal liver cells from E11.5 wild-type embryos. By contrast,
20- to 30-fold fewer cells were recovered from fetal livers of
E11.5 AML1-ETO/1 embryos, and when these cells were plated
in methycellulose at numbers equal to that used in wild-type
cultures, only rare hematopoietic colonies were identified
(Table 2). AML1-ETO expression was confirmed within these
colonies by RT-PCR analysis (data not shown). Taken together,
these data show that expression of AML1-ETO leads to almost a
complete absence of definitive hematopoiesis; however, in
contrast to AML1-deficient embryos,18,19 a few progenitors
could be identified.
Similar to the results obtained with E11.5 fetal livers, the
total number of cells recovered from fetal livers of viable E12.5
and E13.5 AML1-ETO/1 embryos was also 20- to 30-fold less
than that recovered from wild-type embryos. In contrast to the
results obtained with E11.5 embryos, however, cultures of fetal
livers cells from viable E12.5 and E13.5 AML1-ETO/1 em-
bryos contained numerous abnormal multilineage colonies
(Table 2 and Fig 3). These colonies consisted of large, tightly
packed aggregates of differentiating erythroid precursors, mono-
cytes, megakaryoblasts, and hypergranular cells of the myeloid
lineage. Each lineage showed evidence of dysplastic morphol-
ogy with numerous abnormal erythroblast, megakaryoblast, and
multinucleated myeloid cells identified (Fig 3).
To further characterize these abnormal colonies, we collected
cells from individual AML1-ETO/1 or wild-type fetal liver
cultures after 7 to 10 days of growth in methylcellulose,
disaggregated the cells, and then grew them in liquid cultures
either in the presence or absence of IL-3, IL-6, and SCF. Under
these conditions, cellular growth and survival was dependent on
the presence of hematopoietic growth factors, with rapid cell
death observed in their absence. To confirm expression of
AML1-ETO within the expanding hematopoietic population,
Western blot analysis was performed using an affinity purified
ETO-specific rabbit antisera.10 As shown in Fig 4, the AML1-
ETO chimeric protein was not observed in cells from control
cultures but was easily detected within the hematopoietic cells
derived from each of the AML1-ETO/1 fetal liver cultures
(representative results from six cultures presented). The level of
AML1-ETO expression was similar to that of endogenous
AML1 as detected with an AML1-specific antiserum (data not
shown).
To examine the self-renewal capacity of the cells within the
fetal liver-derived colonies, we replated either single colonies or
bulk cell populations in secondary methylcellulose cultures.
When these cells were replated under conditions optimal for the
development of multipotential hematopoietic progenitors, simi-
lar numbers of colonies were observed from both the AML1-
ETO/1 and the control cells (Table 3). However, in contrast to
the wild-type cells, the AML1-ETO/1 cells formed relatively
large dysplastic granulocyte-monocyte and multilineage colo-
nies identical to those seen in the primary cultures (Fig 5A).
Moreover, upon subsequent replating the AML1-ETO/1 cells
continued to form dysplastic mixed colonies at a high efficiency.
Cells from control cultures failed to form colonies after the
seventh replating, whereas AML1-ETO/1 cells continued to
generate colony-forming progenitors in methylcellulose, with-
out any loss in efficiency of colony formation beyond 20
passages (results from the initial 10 passages are shown in Table
3). Although the colony-forming efficiency for the AML1-
ETO/1 cells remained relatively constant, the frequency of
multilineage colonies containing erythroid cells and megakaryo-
cytes decreased with each passage. Remarkably, however,
Fig 3. Morphology of dysplastic AML1-ETO/1 mixed hematopoi-
etic colonies. (A) Abnormal mixed colonies derived from AML1-
ETO/1 fetal liver cells. (B) Cytocentrifuge preparations of cells
contained within these colonies. (Left) Numerous hypergranular
myeloid cells are seen with frequent abnormal binucleated and
trinucleated cells detected. (Right) Illustration of the mixed nature of
the colony with maturing erythroid cells, a monocyte, binucleated
myeloid precursors, and a dysplastic megakaryoblast.
Table 2. Hematopoietic Progenitors in Yolk Sac and Fetal Liver
Source Age Genotype
Number of
Embryos Erythroid Myeloid Mixed
Yolk sac E10.5 1/1 10 30 6 14* 179 6 60 59 6 43
1/KI 10 0 5 6 5 0
Fetal livers E11.5 1/1 23 6 6 6† 61 6 29 13 6 13
1/KI 9 0 4 6 4 4 6 4
E12.5 1/1 7 9 6 5 62 6 36 12 6 7
1/KI 12 0 0 82 6 53‡
E13.5 1/1 7 2 6 1 61 6 11 4 6 3
1/KI 3 0 0 37 6 13
*Mean 6 SD per yolk sac.
†Mean 6 SD per 10,000 fetal liver cells.
‡Abnormal colonies with dysplastic morphology.
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definitive multilineage colonies remained through passage 16
(Fig 5A). The immature dysplastic myeloid and monocytic cells
from the replated colonies readily expanded in liquid cultures
containing IL-3, IL-6, and SCF and coexpressed the myeloid
and monocytic markers GR1 and MAC1 (Fig 5B). Identical
results were obtained from AML1-ETO–expressing fetal liver
hematopoietic progenitors derived from two independently
targeted ES cell clones. Taken together, these data suggest that
expression of AML1-ETO during the establishment of defini-
tive hematopoiesis directly leads to the generation of multipoten-
tial progenitors that have a high self-renewal capacity and
dysplastic maturation.
Murine adult hematopoietic cells transduced with AML1-
ETO exhibit a high self-renewal capacity and readily establish
cell lines in vitro. To further define the role of AML1-ETO in
the growth abnormalities observed in hematopoietic progeni-
tors, we targeted its expression to adult bone marrow–derived
progenitors by retroviral infection (Fig 6). A human AML1-
ETO cDNA was inserted into the murine stem cell retroviral
vector (MSCV), which contains a neomycin resistance gene
(neo) under the control of the phosphoglycerate kinase pro-
moter.36 This vector yields high titer virus capable of efficiently
transducing and expressing genes in murine hematopoietic stem
cells and their progeny and allows direct selection of infected
cells based on resistance to G418. In two independent experi-
ments bone marrow cells obtained from 5-fluorouracil (5-FU)–
treated mice were infected with helper-free retroviral superna-
tants containing MSCV/AML1-ETOneo or MSCVneo. Infected
cells were then plated directly in G418-containing methylcellu-
lose medium under conditions optimal for the growth of
multilineage hematopoietic colonies (Fig 6A and B). Using
viral supernatants with titers of 1 to 5 3 105 G418-resistant
cfu/mL, between 5% and 10% of colony forming progenitors
acquired G418 resistance. Although resistant granulocyte, granu-
locyte-macrophage, macrophage, and mixed colonies were
identified in all cultures, fewer colonies were generated follow-
ing infection with MSCV/AML1-ETOneo. The cause of this
difference is not immediately apparent.
Cells were obtained from primary cultures 8 to 10 days after
plating and replated in secondary methycellulose cultures in the
presence of G418. This process was serially repeated and the
number and morphology of colonies analyzed after each
passage. As shown in Fig 6A and B, a slight increase in the
efficiency of colony formation was noted through the first four
passages for both MSCVneo- and MSCV/AML1-ETOneo–
infected cells. Following passage 4, however, the number of
colony forming progenitors rapidly declined in the MSCVneo
population, with no colonies detected following the 6th passage.
By contrast, MSCV/AML1-ETOneo cells continued to show an
increase in the efficiency of colony formation through subse-
quent passages. In the first experiment (Fig 6A), MSCV/AML1-
ETOneo–infected cells formed colonies at a high efficiency
through 22 generations (results from 13 passages shown).
Similarly, in a second more recent experiment that has to date
been carried through a shorter number of generations (Fig 6B),
MSCVneo cells failed to form colonies after the 5th replating,
whereas MSCV/AML1-ETOneo cells continued to efficiently
form colonies through 13 passages (data from 6 passages
shown).
The replated colonies from MSCV/AML1-ETOneo cells
were composed primarily of immature blasts like cells that
readily expanded into cell lines in liquid cultures in the presence
of IL-3, IL-6, and SCF. These cells expressed c-kit but were
negative for GR-1, Mac-1, Sca-1, and Thy-1 (Fig 6C). In
addition, the cells had the morphology of immature hematopoi-
etic cells with only rare mid-mature myeloid and monocytic
cells identified (Fig 6D). Western blot analysis of cell lysates
from MSCV/AML1-ETOneo–infected populations revealed
AML1-ETO expression (Fig 6E). Taken together, these data
further show that expression of AML1-ETO can directly lead to
the generation of abnormal hematopoietic progenitors with a
high self-renewal capacity.
DISCUSSION
To directly investigate the mechanistic role of the t(8;21)-
encoded AML1-ETO chimeric product in leukemogenesis, we
used gene targeting to create mice with an AML1-ETO ‘‘knock-
in’’ allele that mimics the t(8;21). We now show that murine
Fig 4. AML1-ETO expression in the dysplastic hematopoietic cells. Western blot analysis of total cell lysates prepared from wild-type (Wt.) or
AML1-ETO/1 knock-in (KI) cells. Cell lysates transferred to nitrocellulose membranes were blotted with affinity purified ETO N-terminal peptide
antisera and visualized with supersignal ULTRA chemiluminescence substrate.
Table 3. Serial In Vitro Assays of Fetal Liver Hematopoietic Progenitors
Genotype
In Vitro Passage*
1° 2° 4° 6° 8° 10°
Wild-type 198 6 25† 2,112 6 219 2,533 6 525 13 6 19 0 0
AML1-ETO/1 135 6 60 900 6 154 1,321 6 407 702 6 278 600 6 188 650 6 153
*Hematopoietic cells from methylcellulose cultures were disaggregated, washed, and 3 3 104 viable cells were replated in triplicate into fresh
35-mm methylocellulose cultures.
†Numbers represent myeloid and mixed colonies per 3 3 104 viable cells 6 SD.
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embryos heterozygous for the AML1-ETO knock-in allele have
normal yolk sac–derived primitive hematopoiesis but have a
near total absence of fetal liver-derived definitive hematopoiesis
and die at embryonic day 13.5 from massive bleeding in the
CNS, pericardial sac, and soft tissue. This bleeding diathesis
appeared to result, at least in part, from the absence of
circulating platelets compounded by an evolving anemia due to
the inability to make definitive erythrocytes. Thus, the pheno-
type that resulted from AML1-ETO expression was nearly
identical to the embryonic lethal phenotype seen following
homozygous disruption of either AML118,19 or CBFb.20,21 This
similarity in phenotypes suggests that AML1-ETO effectively
neutralizes the normal biologic activity of the AML1/CBFb
transcriptional factor complex and thus supports published data
Fig 5. Morphology and immu-
nophenotype of AML1-ETO/1
hematopoietic cells. (A, left-to-
right) Typical dysplastic multilin-
eage AML1-ETO/1 colony from
passage 16 with prominent hema-
globinization. Wright-Giemsa–
stained cytocentrifuge prepara-
tion of this colony showing
erythroid, monocytic, and mega-
karyocytic elements. Prominent
alpha naphthyl butyrate cyto-
chemical activity in a cluster of
myeloid and monocytic cells
from within this colony. (B) Flow
cytometeric analysis of surface
antigen expression in AML1-
ETO/1 hematopoietic cells ex-
panded in liquid cultures. Solid
black line represents staining ob-
tained with antibodies specific
for the indicated hematopoietic
antigen. Dashed line corresponds
to the signal obtained with an
isotype matched control anti-
body.
Fig 6. The effects of AML1-
ETO expression on bone mar-
row–derived hematopoietic pro-
genitors. (A and B) Replating
efficiencies in two independent
experiments. The open circles
with red line depict the results of
cell infected with MSCVneo,
whereas the solid squares with
blue line represent the results
from cell infected with MSCV/
AML1-ETOneo. (C) Flow cytomet-
ric analysis of surface antigen
expression on MSCV/AML1-ETO-
neo–infected hematopoietic pro-
genitors derived from the 13th
replating. These cells were car-
ried in liquid cultures for 3 weeks
before immunophenotypic analy-
sis. The solid line represents the
staining obtained with the anti-
body specific for the indicated
antigen. The dashed line repre-
sents the signal obtained with
an isotype matched control anti-
body. (D) Wright-Giemsa–stained
cytocentrifuge preparation of
cells obtained from the 13th re-
plating. (E) Western blot analysis
of cell lysates prepared from
MSCV/AML1-ETOneo–infected
hematopoietic cells using affin-
ity purified antibodies raised
against an AML1–N-terminal
peptide.
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that suggested that AML1-ETO represses AML1-mediated
transcriptional activity through a dominant-negative mecha-
nism.10,31-34
Despite the overall similarity between the phenotypes result-
ing from the loss of AML1/CBFb and expression of AML1-
ETO, two significant differences were observed. First, AML1-
ETO–expressing embryos lived 1 day longer than AML1- or
CBFb-deficient embryos. Second, fetal livers from AML1-ETO–
expressing embryos contained rare hematopoietic progenitors,
whereas no progenitors were detected in the fetal livers of
AML1- or CBFb-deficient embryos. The presence of these cells
in AML1-ETO/1 embryos could, in part, be responsible for the
longer survival of these embryos, given that these cells have the
capacity to differentiate into megakaryocytes and presumably
functional platelets, hematopoietic elements capable of provid-
ing protection from bleeding. These progenitors, however,
failed to establish a functional hematopoietic system within the
developing embryos. Despite this apparent inability to expand
in vivo, these cells readily grew in cultures where they
displayed significant morphologic dysplasia. Moreover, these
AML1-ETO–expressing cells had an abnormally high self-
renewal capacity, a property not seen in normal fetal liver–
derived progenitors but more typical of leukemic cells. The
identical hematopoietic abnormalities were observed in AML1-
ETO/1 heterozygous mice derived from two independent ES
cell lines, suggesting that the phenotype was a direct result of
AML1-ETO expression. This was further confirmed by express-
ing AML1-ETO from a retroviral LTR in adult bone marrow–
derived hematopoietic progenitors. In these experiments, imma-
ture hematopoietic colony forming progenitors were generated
that had a high self-renewal capacity, and again could be readily
established into cell lines when grown in liquid cultures in the
presence of hematopoietic growth factors. Taken together, these
data suggest that AML1-ETO suppresses normal AML1/CBFb
activity and leads to the direct generation of signals that
contribute to the initiation of aberrant hematopoietic cell
proliferation.
Although our data do not directly address the mechanism by
which AML1-ETO mediates the expansion of abnormal hema-
topoietic progenitors, several possibilities are suggested by our
observations: (1) the AML1-ETO chimeric protein may cause
an incomplete repression of normal AML1 transcriptional
activity and thereby result in dysregulated expression of target
genes critical for hematopoiesis; (2) expression of AML1-ETO
may result in novel gain-of-function activities that alter the
transcription of genes normally regulated by AML1/CBFb or
other runt homology domain-containing transcription factors;
(3) novel AML1-ETO–mediated activities may affect the expres-
sion of genes that are not normally regulated by this class of
transcription factors; or (4) a combination of these effects.
Irrespective of the underlying mechanism, our data provide
direct evidence that expression of AML1-ETO contributes to
the expansion of abnormal hematopoietic progenitors by increas-
ing the self-renewal capacity of multipotential hematopoietic
progenitors.
Somewhat surprising was the observation that the dysplastic
AML1-ETO/1 hematopoietic cells failed to expand to appre-
ciable levels within the embryos. Similarly, in preliminary
experiments the AML1-ETO/1 cells fail to induce leukemia in
sublethally irradiated syngeneic or severe combined immunode-
ficiency disease (SCID) mice (Downing and Cai, unpublished
data, March 1998). Despite this lack of growth in vivo, these
cells readily expanded in vitro when cultured in the presence of
IL-3, IL-6, and SCF. Moreover, the cells are growth factor–
dependent both for survival and proliferation. One possible
explanation for these results is that aberrant expression of
AML1-ETO may lead to an altered sensitivity to growth
factor–induced proliferation or differentiation, with high growth
factor concentrations such as those used for in vitro cultures
required for the expansion of the abnormal AML1-ETO progeni-
tors. This possibility is strengthened by the known role that
AML1/CBFb plays in the transcriptional regulation of growth
factors such as GM-CSF and IL-313,14 and growth factor
receptors such as CSF-1R.15 The role of growth factor signaling
pathways in the expansion of this abnormal hematopoietic
population remains to be determined.
Although expression of AML1-ETO resulted in an abnor-
mally high self-renewal capacity in both fetal liver– and adult
bone marrow–derived hematopoietic progenitors, the pheno-
types of the expanding cells differed between these populations.
Immature myelomonocytic cells were obtained following expres-
sion of AML1-ETO in fetal liver–derived progenitors, whereas
more undifferentiated hematopoietic progenitors were obtained
following expression of AML1-ETO in bone marrow–derived
progenitors. These differences may result from expression of
AML1-ETO in distinct stem or progenitor cell populations.
Alternatively, the difference may result from subtle differences
in the pattern of expression of AML1-ETO in the expanding
hematopoietic population that result from the different promot-
ers used to drive its expression. Nevertheless, despite the
observed phenotypic differences both populations showed some
evidence of terminal differentiation. Significantly, in the fetal
liver–derived cells, terminal hematopoietic differentiation was
observed along the myeloid, monocytic, erythroid, and mega-
karyocytic lineages. Thus, these data clearly show that although
AML1-ETO expression leads to abnormal proliferation and
maturation, it does not block terminal hematopoietic differentia-
tion.
A number of investigators have recently used knock-in
approaches to replace one gene with another40 or to create
chimeric oncogenes.41-43 Yergeau and colleagues43 generated
mice heterozygous for an AML1-ETO knock-in allele by using
a strategy that was slightly different from ours. Their data also
showed that expression of AML1-ETO resulted in the death of
embryos at midgestation from CNS hemorrhages and a severe
impairment of fetal liver–derived hematopoiesis. In contrast to
our results, however, they did not observe dysplastic hematopoi-
etic progenitors within the fetal liver but instead identified rare
apparently normal macrophage colonies in yolk sac cultures.
Several differences exist between the targeting strategies used
by the two groups, including the exon targeted and the
transcriptional orientation of the neomycin resistance gene in
relationship to AML1. These differences could result in signifi-
cant changes in the level of expression of the chimeric gene and
thus may be responsible for the phenotypic differences ob-
served. Although the level of AML1-ETO expression was not
documented in Yergeau studies, using our strategy we consis-
tently observed levels of AML1-ETO that were similar to that of
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endogenous AML1. Moreover, easily detectable levels of
AML1-ETO were obtained following retroviral mediated expres-
sion in bone marrow–derived progenitors, and again this level
of expression resulted in an increase in the self-renewal capacity
and in vitro immortilization of these cells.
In summary, we have presented data that suggest that
expression of AML1-ETO results in both the neutralization of
normal AML1/CBFb-mediated activities required for definitive
hematopoiesis and the direct generation of signals that result in
the expansion of dysplastic hematopoietic progenitors. These
AML1-ETO–expressing progenitors are likely to represent the
immediate precursors to full blown leukemic populations. An
investigation of the growth properties and leukemic potential of
the AML1-ETO/1 cells derived through these experiments
should provide valuable insights into the pathways through
which AML1-ETO contributes to human acute myeloid leuke-
mia.
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